Beskrivning
| Land | Finland |
|---|---|
| Lista | First North Finland |
| Sektor | Informationsteknik |
| Industri | Programvara |
Aiforia releases a new CE-IVD marked clinical AI solution for lymph node metastasis detection
Aiforia Technologies Plc, Press Release, September 5, 2025 at 10:30 a.m. EEST
Aiforia Technologies launches a new CE-IVD marked clinical AI solution for lymph node metastasis detection. The Aiforia® Lymph Node Metastasis AI model supports the detection and quantification of metastases of breast cancer, melanoma, and colorectal cancer in lymph nodes from whole slide images. It has been developed in collaboration with the University of Bern.
Lymph node screening is one of the most labor-intensive steps in cancer staging. A single case may require the pathologist to review a multitude of slides under significant time pressure. Aiforia's AI model speeds up the review by providing tools and features that enable rapid navigation to relevant regions within the slides. This enhances workflow efficiency, saving up to 40% of pathologist’s time.
“We are proud to launch again a new CE-IVD marked AI solution compliant with the IVDR, this time in collaboration with the University of Bern. This AI solution assists pathologists in the time-consuming task of identifying metastases and helps ensure none goes undetected. It delivers substantial time savings and improves the consistency in the diagnostic workflow,” says Jukka Tapaninen, CEO of Aiforia.
Further inquiries
Jukka Tapaninen, CEO, Aiforia Technologies Plc
tel. +33 61 041 6686
https://investors.aiforia.com/
Certified Adviser
UB Corporate Finance Ltd
ubcf@unitedbankers.fi
About Aiforia
Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers advanced software solutions that elevate diagnostic capabilities in image analysis, empowering remarkable medical discoveries both today and in the future. With thousands of AI models developed for research use and several diagnostic solutions already deployed, Aiforia is making a significant impact on pathology and healthcare.
Founded in 2013, Aiforia is a publicly traded company with a global presence and thousands of users worldwide. Headquartered in Helsinki, Finland, the company also operates subsidiaries in the United States and France and maintains a network of local representatives across Europe and North America. Aiforia’s diverse team includes experienced AI and software developers, pathologists, medical scientists, and a dedicated commercial team. Together, they are transforming pathology through AI, enabling better care for every patient.
Find out more at www.aiforia.com